De Quervain's disease: Ultrasound-guided release.

Hand surgery & rehabilitation Pub Date : 2025-01-15 DOI:10.1016/j.hansur.2025.102087

Francisco Javier Ferreira Villanova, Vincent Martinel, Olivier Marès

{"title":"De Quervain's disease: Ultrasound-guided release.","authors":"Francisco Javier Ferreira Villanova, Vincent Martinel, Olivier Marès","doi":"10.1016/j.hansur.2025.102087","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the outcomes of a novel antegrade, ultrasound-guided release of the first extensor tendon compartment for treating De Quervain's disease.Methods: We conducted a retrospective, single-center study of 34 patients who underwent ultrasound-guided release of the first extensor compartment for clinically diagnosed De Quervain's disease between June 2022 and December 2023. Inclusion criteria included age >18 years and failure of conservative treatment (e.g., NSAIDs, physiotherapy, and steroid injection) for more than six weeks. Exclusion criteria were prior trigger thumb surgery and documented allergy to local anesthetics. Outcomes were assessed using pain intensity (visual analog scale, VAS), Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) scores, and complication rates.Results: The mean VAS for pain improved from 7.4 to 1.1, and the QuickDASH score improved from 55 to 9.4 at the final follow-up. We recorded three minor complications and no major complications.Conclusion: Ultrasound-guided surgical release of the first extensor compartment for De Quervain's disease is a minimally invasive, technologically advanced, and effective treatment option.","PeriodicalId":94023,"journal":{"name":"Hand surgery & rehabilitation","volume":" ","pages":"102087"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hand surgery & rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hansur.2025.102087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the outcomes of a novel antegrade, ultrasound-guided release of the first extensor tendon compartment for treating De Quervain's disease.

Methods: We conducted a retrospective, single-center study of 34 patients who underwent ultrasound-guided release of the first extensor compartment for clinically diagnosed De Quervain's disease between June 2022 and December 2023. Inclusion criteria included age >18 years and failure of conservative treatment (e.g., NSAIDs, physiotherapy, and steroid injection) for more than six weeks. Exclusion criteria were prior trigger thumb surgery and documented allergy to local anesthetics. Outcomes were assessed using pain intensity (visual analog scale, VAS), Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) scores, and complication rates.

Results: The mean VAS for pain improved from 7.4 to 1.1, and the QuickDASH score improved from 55 to 9.4 at the final follow-up. We recorded three minor complications and no major complications.

Conclusion: Ultrasound-guided surgical release of the first extensor compartment for De Quervain's disease is a minimally invasive, technologically advanced, and effective treatment option.

查看原文本刊更多论文

De Quervain病：超声引导下的释放。

目的：本研究旨在评估一种新型顺行、超声引导下第一伸肌腱室松解术治疗De Quervain病的效果。方法：我们对34例在2022年6月至2023年12月期间接受超声引导下第一伸肌室松解术治疗临床诊断为De Quervain病的患者进行了回顾性、单中心研究。纳入标准为年龄bb0 ~ 18岁，保守治疗（如非甾体抗炎药、物理治疗和类固醇注射）失败超过6周。排除标准为先前的触发拇指手术和有记录的局部麻醉剂过敏。结果通过疼痛强度（视觉模拟量表，VAS）、手臂、肩膀和手的快速残疾（QuickDASH）评分和并发症发生率进行评估。结果：最终随访时疼痛VAS评分从7.4分提高到1.1分，QuickDASH评分从55分提高到9.4分。我们记录了3例轻微并发症，无重大并发症。结论：超声引导下第一伸肌室松解术治疗De Quervain病是一种微创、技术先进、有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hand surgery & rehabilitation

自引率

0.00%

发文量